Carmen Wesley
Primary Care · Aventura, FLNPI 1053838235
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 491 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 55 manufacturers, the largest accounting for just 11.9% — the pattern of someone who eats at a lot of different presentations. Among primary care clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 491 payments — averaging $18.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$830
- GSK$734
- Abbott$637
- Mallinckrodt Hospital Products Inc.$620
- Amgen$556
- plus $5K from 49 others
What the payments were for
- Food & beverage$9,02399%
- Education$1001%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$9,123 in reported general payments places this provider in the 95th percentile of 725 primary care providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 52 | $53,044 |
| EliquisApixaban | 43 | $49,476 |
| MounjaroTirzepatide | 37 | $48,273 |
| XareltoRivaroxaban | 20 | $27,808 |
| JanuviaSitagliptin Phosphate | 17 | $27,275 |
| JardianceEmpagliflozin | 26 | $24,740 |
| FarxigaDapagliflozin Propanediol | 16 | $23,698 |
| RybelsusSemaglutide | 17 | $19,866 |
| LinzessLinaclotide | 16 | $16,920 |
| TrulicityDulaglutide | 12 | $11,450 |
| Aimovig AutoinjectorErenumab-Aooe | 11 | $7,870 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $4,282 |
| SynthroidLevothyroxine Sodium | 29 | $3,620 |
| NovologInsulin Aspart | 20 | $3,276 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $2,194 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $1,083 | $76,18689 claims |
| Lilly USA, LLCMounjaro, Trulicity | $830 | $59,72449 claims |
| PfizerEliquis | $445 | $49,47643 claims |
| AstraZenecaFarxiga, Symbicort | $536 | $27,98131 claims |
| Johnson & JohnsonXarelto | $208 | $27,80820 claims |
| MerckJanuvia | $149 | $27,27517 claims |
| Boehringer IngelheimJardiance | $409 | $24,74026 claims |
| AbbVieLinzess, Synthroid | $392 | $20,53945 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 725 primary care providers in Florida.
Other primary care in Aventura
- Paul ChanOrlando$447K
- Jenny WestPensacola$80K
- Railet RodriguezAltamonte Springs$14K
- Kevin HanawayFort Lauderdale$12K
- Kelly ChewningAlachua$11K
- Yolanda PalmeroSaint Cloud$11K
- Erica ClarkCitrus Springs$11K
- Michelle SelvaggiLakewood Ranch$10K
- Kristen DeasonTallahassee$10K
- Robert PerriPalm Coast$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.